[Pre-print, not peer reviewed]<\/i> The Moderna and Pfizer vaccines were 89% effective (95% CI: 68-97%) in preventing SARS-CoV-2 infection occurring at least 36 days after the first dose in a 1:1 propensity score matched analysis of over 60,000 individuals in the US between December 2020 to February 2021. Among those subsequently diagnosed with COVID-19, vaccinated patients had significantly lower 14-day hospital admission rates compared to matched unvaccinated counterparts (3.7% vs 9.2%). Vaccine efficacy 7 days after receiving the first dose was 54% (95% CI: 41-64%), which increased over time to a maximum of 93% (95% CI: 70-99%) between days 36-42.<\/p>\n
The authors note that a key limitation of the study was shorter follow-up time compared to the phase 3 trials (27 days vs.\u00a080-90 days); 45% of the vaccinated cohort had only received one vaccine dose for some efficacy analyses. Additionally, bias on seeking PCR testing between vaccinated and unvaccinated patients was not addressed.<\/p>\n
Pawlowski et al.\u00a0(Feb 18, 2021). FDA-Authorized COVID-19 Vaccines Are Effective per Real-World Evidence Synthesized across a Multi-State Health System. Pre-print downloaded Feb 18 from <\/i>https:\/\/doi.org\/10.1101\/2021.02.15.21251623<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" [Pre-print, not peer reviewed] The Moderna and Pfizer vaccines were 89% effective (95% CI: 68-97%) in preventing SARS-CoV-2 infection occurring at least 36 days after the first dose in a 1:1 propensity score matched analysis of over 60,000 individuals in the US between December 2020 to February 2021. Among those subsequently diagnosed with COVID-19, vaccinated…<\/p>\n